UnitedHealth Group's stock jumped nearly 8% on Thursday after reporting impressive second-quarter earnings. The company posted an adjusted earnings per share (EPS) of $6.38, significantly exceeding analysts' expectations of $4.91. Revenue also impressed, reaching $112 billion, beating the Wall Street forecast of $110.8 billion.

One of the key metrics that analysts were closely monitoring was the medical-cost ratio, which fell to 86.7%. This figure is a marked improvement from 89.4% a year ago and is below the anticipated 88.4% by analysts. A lower medical-cost ratio indicates that the company is retaining a larger portion of its premium income. Management attributed this success to various strategies, including product design changes, enhanced medical management, and better pricing alignment.

Upgraded Guidance and Competitor Impact

In light of its strong performance, UnitedHealth has increased its full-year adjusted EPS guidance to a range of $19.50 to $20.00, up from a previous minimum of $18.25, surpassing analysts' projected EPS of $18.49.

The positive trends for UnitedHealth also had a ripple effect on its competitors. Both Humana and CVS Health, which operates Aetna, saw their stocks rise by around 1% following UnitedHealth's announcement. These companies, like UnitedHealth, are involved in the Medicare Advantage market, which has been facing pressure due to rising costs. UnitedHealth has taken steps to rein in its Medicare Advantage enrollment, anticipating a decrease of approximately 1.1 million beneficiaries.

Analyst Upgrades and Concerns

Following the earnings report, Baird analyst Michael Ha raised his rating on UnitedHealth from Sell to Hold, and increased his price target from $287 to $453. He expressed growing confidence in the company's near-term margin improvements within Medicare Advantage and noted a slowdown in healthcare cost trends.

However, Ha remains cautious about Optum Health's long-term margin targets, especially with anticipated changes to the Medicare Advantage risk model expected in early 2027. This indicates that while the immediate outlook appears strong, there are long-term challenges to consider.

This material is for informational purposes only and should not be considered financial advice.